Voyager Therapeutics (NASDAQ:VYGR) Lowered to “Hold” at StockNews.com

StockNews.com cut shares of Voyager Therapeutics (NASDAQ:VYGR) from a buy rating to a hold rating in a research report report published on Friday.

Other analysts have also issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating and set a $30.00 price objective on shares of Voyager Therapeutics in a report on Thursday. Wedbush dropped their price target on Voyager Therapeutics from $8.00 to $7.00 and set a “neutral” rating for the company in a report on Wednesday, August 7th. Leerink Partners assumed coverage on Voyager Therapeutics in a research report on Wednesday, October 16th. They issued an “outperform” rating and a $15.00 price objective for the company. Finally, Leerink Partnrs upgraded Voyager Therapeutics to a “strong-buy” rating in a report on Wednesday, October 16th. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $17.43.

Voyager Therapeutics Price Performance

Shares of VYGR stock opened at $6.75 on Friday. The stock’s fifty day simple moving average is $6.55 and its 200 day simple moving average is $7.63. Voyager Therapeutics has a one year low of $5.71 and a one year high of $11.72. The firm has a market cap of $367.16 million, a price-to-earnings ratio of -135.00 and a beta of 0.91.

Voyager Therapeutics (NASDAQ:VYGR) last issued its earnings results on Tuesday, August 6th. The company reported ($0.18) EPS for the quarter, beating the consensus estimate of ($0.38) by $0.20. The company had revenue of $29.58 million for the quarter, compared to the consensus estimate of $11.52 million. Voyager Therapeutics had a net margin of 6.28% and a return on equity of 3.31%. During the same quarter in the previous year, the company earned ($0.51) EPS. On average, research analysts anticipate that Voyager Therapeutics will post -1.27 earnings per share for the current year.

Insider Transactions at Voyager Therapeutics

In related news, insider Sandell Jacquelyn Fahey sold 5,999 shares of Voyager Therapeutics stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $5.82, for a total value of $34,914.18. Following the completion of the sale, the insider now directly owns 86,001 shares in the company, valued at $500,525.82. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.53% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Voyager Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Ameritas Investment Partners Inc. raised its position in shares of Voyager Therapeutics by 49.6% during the 1st quarter. Ameritas Investment Partners Inc. now owns 3,923 shares of the company’s stock valued at $37,000 after acquiring an additional 1,300 shares during the last quarter. Plato Investment Management Ltd acquired a new stake in shares of Voyager Therapeutics during the first quarter worth $38,000. China Universal Asset Management Co. Ltd. grew its stake in shares of Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock worth $61,000 after purchasing an additional 4,098 shares during the period. SG Americas Securities LLC bought a new stake in Voyager Therapeutics in the second quarter valued at about $85,000. Finally, ProShare Advisors LLC acquired a new position in Voyager Therapeutics in the first quarter valued at about $101,000. 48.03% of the stock is owned by institutional investors.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.